Steris has announced that together with Synergy Health plc, it will contest the U.S. Federal Trade Commission’s efforts to block the proposed merger of the two companies. This comes in response to an administrative complaint filed by the FTC. The Commission has claimed that the deal violates antitrust laws, as it may potentially reduce competition in the regional markets for sterilization of products using radiation.
In Oct 2014, US-based Steris had proposed to buy U.K.-based Synergy Health for $1.9 billion in cash and stock. The acquisition aims at combining Steris’ Infection Prevention and Services with Synergy’s Hospital Sterilization Services business.
The deal is in line with other tax inversion mergers announced last year that were targeted to cut down on the tax bills of US companies by shifting their tax base overseas.
Full content: The National Law Review
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
ConocoPhillips Acquires Marathon Oil for $22.5 Billion in Major Energy Sector Consolidation
May 29, 2024 by
CPI
Judge Denies Amazon’s Bid to Dismiss FTC Lawsuit Over Prime Membership Practices
May 29, 2024 by
CPI
Germany and France Advocate for Major EU Competition Reform
May 29, 2024 by
CPI
Equifax Accused of Monopolizing Employment Verification Market in New Suit
May 29, 2024 by
CPI
Car Battery Makers to Challenge EU Cartel Charges in Brussels
May 29, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI